|Bid||32.69 x 1200|
|Ask||32.70 x 800|
|Day's Range||29.35 - 33.35|
|52 Week Range||23.51 - 99.95|
|Beta (5Y Monthly)||1.92|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 05, 2021 - Aug 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||47.33|
Cathie Wood's ARK Invest is still red-hot, but now in the opposite way: It's getting burned by many collapsing stocks including some in the S&P 500.
Earlier this morning, we issued a press release providing our financial results and corporate updates for the first quarter of 2021. As a reminder, various remarks that we make during this call about the company's future expectations, plans, and prospects constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our most recent annual report on Form 10-K, which is on file with the SEC.
Editas Medicine (NASDAQ: EDIT) entered 2021 with tremendous momentum. The company announced a Q1 net loss of $56.7 million, or $0.86 per share, based on generally accepted accounting principles (GAAP). In the prior-year period, Editas posted a GAAP net loss of $37.7 million, or $0.69 per share.